Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.

Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA.

J Virol. 2013 Apr;87(8):4176-84. doi: 10.1128/JVI.03486-12. Epub 2013 Jan 30.

2.

Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease.

King NM, Prabu-Jeyabalan M, Bandaranayake RM, Nalam MN, Nalivaika EA, Özen A, Haliloğlu T, Yilmaz NK, Schiffer CA.

ACS Chem Biol. 2012 Sep 21;7(9):1536-46. Epub 2012 Jul 2.

3.

The PA domain is crucial for determining optimum substrate length for soybean protease C1: structure and kinetics correlate with molecular function.

Tan-Wilson A, Bandak B, Prabu-Jeyabalan M.

Plant Physiol Biochem. 2012 Apr;53:27-32. doi: 10.1016/j.plaphy.2012.01.005. Epub 2012 Jan 10.

PMID:
22285412
4.

Molecular Basis for Drug Resistance in HIV-1 Protease.

Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MN, Nalivaika EA, Ozen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA.

Viruses. 2010 Nov;2(11):2509-35. doi: 10.3390/v2112509. Epub 2010 Nov 12.

5.

Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6.

Bandaranayake RM, Prabu-Jeyabalan M, Kakizawa J, Sugiura W, Schiffer CA.

J Virol. 2008 Jul;82(13):6762-6. doi: 10.1128/JVI.00018-08. Epub 2008 Apr 23.

6.

Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.

Altman MD, Nalivaika EA, Prabu-Jeyabalan M, Schiffer CA, Tidor B.

Proteins. 2008 Feb 15;70(3):678-94.

7.

Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.

Foulkes JE, Prabu-Jeyabalan M, Cooper D, Henderson GJ, Harris J, Swanstrom R, Schiffer CA.

J Virol. 2006 Jul;80(14):6906-16.

8.

Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.

Prabu-Jeyabalan M, King NM, Nalivaika EA, Heilek-Snyder G, Cammack N, Schiffer CA.

Antimicrob Agents Chemother. 2006 Apr;50(4):1518-21.

9.
10.

Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

Surleraux DL, de Kock HA, Verschueren WG, Pille GM, Maes LJ, Peeters A, Vendeville S, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB.

J Med Chem. 2005 Mar 24;48(6):1965-73.

PMID:
15771440
11.

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB.

J Med Chem. 2005 Mar 24;48(6):1813-22.

PMID:
15771427
12.
13.

Combating susceptibility to drug resistance: lessons from HIV-1 protease.

King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA.

Chem Biol. 2004 Oct;11(10):1333-8.

14.

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Béthune MP, Schiffer CA.

J Virol. 2004 Nov;78(21):12012-21.

15.
16.
17.

Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

King NM, Melnick L, Prabu-Jeyabalan M, Nalivaika EA, Yang SS, Gao Y, Nie X, Zepp C, Heefner DL, Schiffer CA.

Protein Sci. 2002 Feb;11(2):418-29.

18.

How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease.

Prabu-Jeyabalan M, Nalivaika E, Schiffer CA.

J Mol Biol. 2000 Sep 1;301(5):1207-20.

PMID:
10966816

Supplemental Content

Loading ...
Support Center